{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Progression"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Response was assessed based on Bone marrow biopsy and CT scan. Best responses are used for Response Rate and CR and PR only.\n\nComplete Response - CR:\n\n• Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.\n\nPartial Response - PR:\n\n• At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses.\n\nStable Disease - SD:\n\n• A patient is considered to have SD when he or she fails to attain the criteria needed for a CR or PR, but does not fulfill those for progressive disease\n\nRelapsed Disease:\n\n• Lymph nodes should be considered abnormal if the long axis is more than 1.5 cm regardless of the short axis.","groups":[{"description":"Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22,\n\nOfatumumab and Bortezomib: Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22- in the induction phase Ofatumumab 1000 mg IV on day 1- will receive in the maintenance phase Patients will remain until progression","id":"OG000","title":"Ofatumumab IV,"}],"paramType":"NUMBER","populationDescription":"8/10 patients were evaluable as 2 withdrew","reportingStatus":"POSTED","timeFrame":"Bone Marrow Biopsy: Every 2 months for 1 year then every 4 months until progression for approximately 1 year/Via CT scan: every 4 months until progression, for a total of approximately 2 years","title":"Overall Response Rate (ORR) of the Combination of Ofatumumab and Bortezomib in Patients Receiving Study Treatment","type":"PRIMARY","unitOfMeasure":"participants"}